Related Experiment Video
Updated: May 27, 2025

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance
Zhanshen Wu1, Yang Zhao1, Xiangyu Zhang1
1Department of Pharmacy, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background:
Previous studies have explored the association between levetiracetam (LEV) and severe cutaneous adverse reactions (SCARs). However, most investigations have relied on clinical trial data or case reports from individual medical centers. Consequently, the precise relationship between LEV and SCARs in real-world settings remains elusive.
Research Design And Methods:
Data from the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases were analyzed, focusing on LEV-associated SCAR events utilizing disproportionality analysis methods.
Results:
This study identified a significant correlation between LEV and SCARs (p < 0.05). However, combined analyses with other antiepileptic drugs revealed that the association of LEV with SCARs was comparatively weaker (p < 0.05). Univariate logistic regression analysis indicated that males, individuals aged 45 ~ 65 years, and combination therapy with eslicarbazepine, phenytoin, carbamazepine, and lamotrigine significantly increased the risk of developing SCARs (p < 0.05). Notably, SCARs were most likely to occur within the initial week of LEV treatment (39.39%).
Conclusions:
Despite certain limitations, this study offers updated insights into the association between LEV and SCARs. These findings underscore the significance of monitoring and actively managing LEV-associated SCARs to promote its safe and effective use.
More Related Videos
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Drug Absorption: Overview
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
Pharmacokinetics: Overview
Analysis of Population Pharmacokinetic Data